Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Predictive Modelling of Overall Survival in Adult Patients with Primary Diffuse Large B-cell Lymphoma of the Breast Using the Surveillance, Epidemiology, and End Results (SEER) Database

Author(s): Yishuai Liu, Haifeng Han, Hong Wei, Xinlong Wang, Zhaotang Luan and Kun Jiang*

Volume 19, Issue 3, 2024

Published on: 01 August, 2023

Page: [373 - 382] Pages: 10

DOI: 10.2174/1574892818666230718153721

Price: $65

Abstract

Objective: We aimed to identify critical clinical features to develop an accurate webbased prediction model for estimating the overall survival (OS) of primary breast diffuse large Bcell lymphoma (PB-DLBCL) adult patients.

Methods: We first included all PB-DLBCL cases with available covariates retrieved from the Surveillance, Epidemiology, and End Results database. We sequentially performed univariate and multivariate Cox regression approaches to identify the predictors independently associated with prognosis, and all the predictors that passed these tests were then constructed to build a nomogram for predicting 3-, 5-, and 10-year survival rates of patients. The C-index and the receiver operating characteristic curve (ROC) were used to evaluate the prediction discrimination, and the calibration curve was applied to estimate the calibration.

Results: A total of PB-DLBCL adult patients were included (median age was 69 with the interquartile range [IQR] of 57-79 years), of which 466 (70%) were randomly allocated to the development cohort, and the remaining cases were collected for validation. Using three identified independent predictors (i.e., age, stage, and radiation), an accurate nomogram for predicting OS was developed and validated. The C-indices of our nomogram were both relatively acceptable, with 0.74 (95% CI: 0.71-0.78) and 0.72 (95% CI: 0.70-0.75) for the development and validation cohorts, respectively. The calibration curves also accurately predicted the prognosis of PB-DLBCL in all cases. In addition, ROC curves showed our nomogram to possess superior predictive ability compared to any single variable. To visually present this prediction model, a convenient webbased tool was implemented based on our prognostic nomogram.

Conclusion: For patients with PB-DLBCL, a more convenient and accurate web-based prediction model was developed and validated, which showed relatively good performances in both discrimination and calibration during model development and validation. External evaluation and validation are warranted by further independent studies.

Keywords: Overall survival, web-based, diffuse large B-cell lymphoma, SEER, nomogram, Cox regression.

« Previous Next »
[1]
Validire P, Capovilla M, Asselain B, et al. Primary breast non-Hodgkin’s lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol 2009; 84(3): 133-9.
[http://dx.doi.org/10.1002/ajh.21353] [PMID: 19199367]
[2]
Alexandra Thomas, Brian KL, Altekruse S, et al. Primary breast lymphoma in the United States: 1975-2013. J Natl Cancer Inst 2017; 109(6): djw294.
[http://dx.doi.org/10.1093/jnci/djw294] [PMID: 28376147]
[3]
Cheah CY, Campbell BA, Seymour JF. Primary breast lymphoma. Cancer Treat Rev 2014; 40(8): 900-8.
[http://dx.doi.org/10.1016/j.ctrv.2014.05.010] [PMID: 24953564]
[4]
Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer 1972; 29(6): 1705-12.
[http://dx.doi.org/10.1002/1097-0142(197206)29:6<1705:AID-CNCR2820290640>3.0.CO;2-I] [PMID: 4555557]
[5]
Aviv A, Tadmor T, Polliack A. Primary diffuse large B-cell lymphoma of the breast: Looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol 2013; 24(9): 2236-44.
[http://dx.doi.org/10.1093/annonc/mdt192] [PMID: 23712546]
[6]
Lafleur B. Methods for subtyping diffuse large B-cell lymphoma (DLBCL). U. S. Patent. US 11384399B2, , 2022.
[7]
Anne N, Pallapothu R. Lymphoma of the breast: A mimic of inflammatory breast cancer. World J Surg Oncol 2011; 9(1): 125.
[http://dx.doi.org/10.1186/1477-7819-9-125] [PMID: 21989047]
[8]
Luo H, Yi P, Wang W, et al. Clinicopathological features, treatment, and prognosis in primary diffuse large b cell lymphoma of the breast: a retrospective study of 46 patients. Med Sci Monit 2019; 25: 8671-82.
[http://dx.doi.org/10.12659/MSM.917550] [PMID: 31734687]
[9]
Picasso R, Tagliafico A, Calabrese M, et al. Primary and secondary breast lymphoma: focus on epidemiology and imaging features. Pathol Oncol Res 2020; 26(3): 1483-8.
[http://dx.doi.org/10.1007/s12253-019-00730-0] [PMID: 31428995]
[10]
Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: More than meets the eye. Lancet Oncol 2015; 16(4): e173-80.
[http://dx.doi.org/10.1016/S1470-2045(14)71116-7] [PMID: 25846097]
[11]
Nishikawa A, Kasai H, Koyama Y, et al. Synchronous ipsilateral carcinoma of the accessory mammary gland and primary lymphoma of the breast with subsequent rectal carcinoma: Report of a case. World J Surg Oncol 2014; 12(1): 286.
[http://dx.doi.org/10.1186/1477-7819-12-286] [PMID: 25217973]
[12]
Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: Prognostic factors and outcomes of a study by the international extranodal lymphoma study group. Ann Oncol 2008; 19(2): 233-41.
[http://dx.doi.org/10.1093/annonc/mdm471] [PMID: 17932394]
[13]
Jung SP, Kim M, Han KM, et al. Primary breast lymphoma: A single institution’s experience. J Korean Surg Soc 2013; 84(5): 267-72.
[http://dx.doi.org/10.4174/jkss.2013.84.5.267] [PMID: 23646311]
[14]
Yhim HY, Kang HJ, Choi YH, et al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer 2010; 10(1): 321.
[http://dx.doi.org/10.1186/1471-2407-10-321] [PMID: 20569446]
[15]
Zhao S, Zhang QY, Ma WJ, et al. Analysis of 31 cases of primary breast lymphoma: The effect of nodal involvement and microvascular density. Clin Lymphoma Myeloma Leuk 2011; 11(1): 33-7.
[http://dx.doi.org/10.3816/CLML.2011.n.004] [PMID: 21454188]
[16]
Kim SJ, Kang HJ, Kim JS, et al. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: Surgical resection followed by chemotherapy versus chemotherapy alone. Blood 2011; 117(6): 1958-65.
[http://dx.doi.org/10.1182/blood-2010-06-288480] [PMID: 21148334]
[17]
Shi Y, Han Y, Yang J, et al. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res 2019; 31(1): 152-61.
[http://dx.doi.org/10.21147/j.issn.1000-9604.2019.01.10] [PMID: 30996573]
[18]
Zhang H, Ma G, Du S, et al. Nomogram for predicting cancer specific survival in inflammatory breast carcinoma: A SEER population-based study. PeerJ 2019; 7: e7659.
[http://dx.doi.org/10.7717/peerj.7659] [PMID: 31576238]
[19]
Zhong H, Chen J, Cheng S, et al. Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin’s lymphoma. EBioMedicine 2019; 41: 167-74.
[http://dx.doi.org/10.1016/j.ebiom.2019.02.048] [PMID: 30827933]
[20]
Jennings WC, Baker RS, Murray SS, et al. Primary breast lymphoma: The role of mastectomy and the importance of lymph node status. Ann Surg 2007; 245(5): 784-9.
[http://dx.doi.org/10.1097/01.sla.0000254418.90192.59] [PMID: 17457172]
[21]
Raj SD, Shurafa M, Shah Z, Raj KM, Fishman MDC, Dialani VM. Primary and secondary breast lymphoma: Clinical, pathologic, and multimodality imaging review. Radiographics 2019; 39(3): 610-25.
[http://dx.doi.org/10.1148/rg.2019180097] [PMID: 30924754]
[22]
Nan S, Xie C, Shi Y, et al. Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: A Surveillance, Epidemiology and End Results (SEER) analysis. Cancer Manag Res 2019; 11: 1433-42.
[http://dx.doi.org/10.2147/CMAR.S185212] [PMID: 30863154]
[23]
Wang J, Ren W, Zhang C, Wang X. A new staging system based on the dynamic prognostic nomogram for elderly patients with primary gastrointestinal diffuse large B-Cell lymphoma. Front Med 2022; 9: 860993.
[http://dx.doi.org/10.3389/fmed.2022.860993] [PMID: 35586073]
[24]
Lalani N, Winkfield KM, Soto DE, et al. Management and outcomes of women diagnosed with primary breast lymphoma: A multi-institution experience. Breast Cancer Res Treat 2018; 169(1): 197-202.
[http://dx.doi.org/10.1007/s10549-018-4671-8] [PMID: 29356916]
[25]
Major A, Smith DE, Ghosh D, Rabinovitch R, Kamdar M. Risk and subtypes of secondary primary malignancies in diffuse large B‐cell lymphoma survivors change over time based on stage at diagnosis. Cancer 2020; 126(1): 189-201.
[http://dx.doi.org/10.1002/cncr.32513] [PMID: 31509235]
[26]
Saito B, Shiozawa E, Usui T, et al. Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma. Leukemia 2007; 21(12): 2563-6.
[http://dx.doi.org/10.1038/sj.leu.2404844] [PMID: 17597802]
[27]
Yhim HY, Kim JS, Kang HJ, et al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Int J Cancer 2012; 131(1): 235-43.
[http://dx.doi.org/10.1002/ijc.26352] [PMID: 21823120]

Rights & Permissions Print Cite
Article Metrics
13
2
© 2024 Bentham Science Publishers | Privacy Policy